Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme 2 selected

Guidance programme

Showing 761 to 770 of 911

TitleReference numberPublishedLast updated
Secukinumab for treating active ankylosing spondylitisTA407
Secukinumab for treating active non-radiographic axial spondyloarthritisTA719
Secukinumab for treating moderate to severe hidradenitis suppurativaTA935
Secukinumab for treating moderate to severe plaque psoriasisTA350
Secukinumab for treating moderate to severe plaque psoriasis in children and young peopleTA734
Selective internal radiation therapies for treating hepatocellular carcinomaTA688
Selinexor with bortezomib and dexamethasone for previously treated multiple myelomaTA974
Selinexor with dexamethasone for treating relapsed and refractory multiple myeloma after 4 or more treatmentsTA970
Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and overTA1038
Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and overTA1039

Results per page

  1. 10
  2. 25
  3. 50
  4. All